5.05 USD
-0.23 (-4.36%)
Taking everything into account, CYCCP scores 3 out of 10 in our fundamental rating. CYCCP was compared to 525 industry peers in the Biotechnology industry. CYCCP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYCCP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CYCCP has reported negative net income.
- In the past year CYCCP has reported a negative cash flow from operations.
- CYCCP had negative earnings in each of the past 5 years.
- In the past 5 years CYCCP always reported negative operating cash flow.
1.2 Ratios
- CYCCP's Return On Assets of -146.06% is on the low side compared to the rest of the industry. CYCCP is outperformed by 84.10% of its industry peers.
- CYCCP has a Return On Equity of -177.03%. This is in the lower half of the industry: CYCCP underperforms 64.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -146.06% | ||
| ROE | -177.03% | ||
| ROIC | N/A |
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for CYCCP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CYCCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CYCCP has more shares outstanding
- The number of shares outstanding for CYCCP has been increased compared to 5 years ago.
- There is no outstanding debt for CYCCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -138.50, we must say that CYCCP is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -138.50, CYCCP is not doing good in the industry: 97.04% of the companies in the same industry are doing better.
- CYCCP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -138.5 |
ROIC/WACCN/A
WACC9.66%
2.3 Liquidity
- CYCCP has a Current Ratio of 5.77. This indicates that CYCCP is financially healthy and has no problem in meeting its short term obligations.
- CYCCP's Current ratio of 5.77 is fine compared to the rest of the industry. CYCCP outperforms 61.74% of its industry peers.
- CYCCP has a Quick Ratio of 5.77. This indicates that CYCCP is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of CYCCP (5.77) is better than 61.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.77 | ||
| Quick Ratio | 5.77 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 96.85% over the past year.
- The Revenue for CYCCP has decreased by -87.50% in the past year. This is quite bad
EPS 1Y (TTM)96.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.43%
Revenue 1Y (TTM)-87.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
- The Earnings Per Share is expected to grow by 36.35% on average over the next years. This is a very strong growth
- Based on estimates for the next years, CYCCP will show a very strong growth in Revenue. The Revenue will grow by 385.15% on average per year.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5Y36.35%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5Y385.15%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CYCCP. In the last year negative earnings were reported.
- Also next year CYCCP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CYCCP's earnings are expected to grow with 57.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%
5. Dividend
5.1 Amount
- No dividends for CYCCP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP / CYCCP FAQ
What is the ChartMill fundamental rating of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CYCCP.
Can you provide the valuation status for CYCLACEL PHARMACEUTICALS - CYCC 6 PERP?
ChartMill assigns a valuation rating of 1 / 10 to CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP). This can be considered as Overvalued.
How profitable is CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) has a profitability rating of 0 / 10.
What is the financial health of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) stock?
The financial health rating of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) is 6 / 10.
Can you provide the expected EPS growth for CYCCP stock?
The Earnings per Share (EPS) of CYCLACEL PHARMACEUTICALS - CYCC 6 PERP (CYCCP) is expected to grow by 39.49% in the next year.